Let’s be honest—tariffs rarely benefit anyone in the long run. They drive up the cost of raw materials, spark trade tensions, make markets less competitive, and ultimately lead to higher prices for end users.
The latest US tariffs on pharmaceutical imports are shaking things up for companies in ways that aren’t making headlines. While most of the attention has been on industries like cars and lumber, the pharmaceutical world is quietly dealing with its own set of challenges. These new policies aren’t just impacting drug production; they’re also throwing a wrench into the logistics of getting drug samples and educational materials into the hands of healthcare providers. And since those materials play a key role in engagement, education, and prescribing decisions, the ripple effect is real.
For sales and marketing managers, staying ahead of these shifts is critical. Having a clear understanding of how tariffs disrupt fulfillment processes can help providers still have access to the materials they need while avoiding compliance headaches and costly delays.
Rising Costs and Supply Chain Disruptions
As U.S. pharmaceutical import tariffs drive up costs and disrupt supply chains, major drugmakers are taking decisive action to reduce risk in their operations. For example, Eli Lilly recently announced a $27 billion investment to build four new manufacturing facilities in the U.S1., while Johnson & Johnson is committing over $55 billion to expand domestic production2. Though it will take time for these facilities to be built and fully operational—potentially extending into the next administration or policy shift—the goal is clear: reduce dependence on increasingly expensive and unpredictable foreign supply chains.
But the impact isn’t limited to drug production. Tariffs on lumber have sent paper and printing costs soaring, making it more expensive to produce drug samples and sales literature—essential resources for healthcare providers.
Some sources estimate that the 25% tariff on Canadian lumber, responsible for about 80% of U.S. newsprint, has set off a ripple effect across the industry. Printing costs are climbing by 4–12%, and some businesses say the added expense could erase their profit margins entirely. Even U.S. suppliers are raising prices, adding more pressure to an already strained printing and paper market3.
Companies with cross-border operations, particularly in Canada, face even greater logistical hurdles as they navigate rising material costs and tariff-related expenses. In the near term, pharmaceutical firms should act swiftly to minimize disruptions, maintain provider access, and stay ahead of compliance challenges and potential delays.
Challenges in Sales Material Fulfillment
Sales materials like brochures, printed educational pieces, and promotional kits typically rely on international vendors and complex kitting operations. With tariffs now impacting paper goods, plastics, and packaging components, fulfillment is slower, less predictable, and more expensive.
These delays don’t just create logistical headaches—they can stall new product rollouts, prevent timely physician education, and hurt field force effectiveness. Even more critically, delays in delivering required samples, especially those tied to REMS programs (related to FDA drug safety) or black box warnings(how the FDA highlights serious or life-threatening risks), can raise compliance concerns.
How Pharma Companies Are Responding
As tariffs drive up the cost of imported materials, pharmaceutical companies are reevaluating how they manage sales collateral, sample fulfillment, and HCP engagement. Brands are modernizing their approach to stay competitive by adopting strategies that reduce dependency on imports while boosting efficiency, flexibility, and speed across operations.
In addition to domestic production, to rely less on international suppliers and avoid unpredictable tariff costs, here’s how companies are responding—and how Circulo Pharma supports each approach:
- Digital Transformation: Pharmaceutical companies are shifting away from traditional printed sales materials and embracing digital alternatives. By distributing approved content through secure digital platforms, brands can ensure that HCPs and field reps always have access to the most up-to-date materials—instantly, cost-effectively, and without the delays or expenses associated with printing and shipping.
- On-Demand Fulfillment: Many companies are turning to on-demand print and fulfillment for materials that still require physical delivery. This eliminates the need for large print runs and warehousing, reducing waste and overhead while enabling a faster, more flexible response to changing needs.
- Supply Chain Diversification: Pharma companies are diversifying their supplier networks and logistics partners to reduce vulnerability to global trade disruptions and tariffs. This creates more resilient operations and enables faster responses when delays or restrictions arise. By spreading risk across multiple sources, companies are better equipped to maintain consistent delivery of samples and sales materials.
How Circulo Helps Support Pharma’s Strategic Response
As companies navigate the rising costs and complexity introduced by U.S. tariffs, Circulo Pharma provides actionable strategies and technology-driven solutions to help reduce expenses and maintain fulfillment efficiency.
Companies can offset costs by nearshoring fulfillment to non-tariff regions like Mexico or by partnering with Circulo’s U.S.-based 3PL network, which specializes in pharma-compliant logistics. In addition, bulk procurement and consolidated kitting services help lower per-unit costs while improving speed and accuracy in delivery.
Circulo also offers on-demand print fulfillment, allowing pharma teams to request and ship only what’s needed, when it’s needed. This eliminates the waste and cost of outdated or excess inventory, supports just-in-time distribution, and ensures materials are always up to date and compliant. It’s a more flexible, scalable alternative to large print runs, especially in an environment where speed and accuracy are critical.
To further streamline operations, Circulo enables digital fulfillment of sales materials, replacing printed collateral with flexible, trackable, QR-code-enabled resources that give reps more options in the field while reducing printing and shipping expenses.
On the technology side, Circulo’s HCP engagement platform includes inventory optimization tools that leverage predictive analytics to reduce waste and avoid overstocking. Integrated CRM and fulfillment systems provide real-time tracking and ensure that sample requests, approvals, and deliveries remain compliant and efficient from end to end.
Together, these solutions equip pharma sales and marketing teams with the tools they need to adapt quickly, lower operational costs, and maintain strong, compliant HCP engagement—even in a rapidly changing global trade environment.
Regulatory and Compliance Considerations
Tariffs don’t just raise costs—they can also create regulatory headaches. When drug samples or sales materials are delayed, it can put companies at risk of falling out of compliance with federal regulations. Whether it’s FDA requirements in the U.S. or Health Canada guidelines, timely delivery is critical, especially for materials tied to REMS programs, severe warnings, or product launches with tight timelines. These disruptions can slow down how quickly new treatments reach the market, making it harder to keep healthcare providers informed and engaged.
To stay ahead of these challenges, pharmaceutical companies are turning to more innovative fulfillment systems—ones that are fast and reliable and built with compliance in mind. That means having clear documentation, expiration tracking, and tools to flag potential issues before they become real problems. With the right systems in place, teams can respond quickly, keep everything running smoothly, and maintain the high standards regulators expect—on both sides of the border.
The Bottom Line
Tariffs may be out of your control, but how you respond to them isn’t. As fulfillment and compliance challenges mount, the companies that succeed won’t be the ones that wait out the disruption—they’ll be the ones that adapt faster, operate smarter, and build resilience into every layer of their sales operations.
If you’re ready to future-proof your sample and sales material fulfillment, let’s talk. Schedule a personalized demo to see how Circulo Pharma can help you streamline workflows, reduce costs, and stay fully compliant, no matter how the global landscape shifts next.
1. nbcnewyork.com/news/business/money-report/eli-lilly-plans-at-least-27-billion-in-new-u-s-manufacturing-investments/6164575/
2. jnj.com/media-center/press-releases/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years
3. printing.org/content/2025/02/10/the-impact-of-tariffs-on-the-u.s.-printing-industry
